2 19 December 2025 false false false false true false false false false false false true false false false false false false No description of principal activity 2024-04-01 Sage Accounts Production Advanced 2024 - FRS102_2024 753,114 753,114 753,114 xbrli:pure xbrli:shares iso4217:GBP 15430379 2024-04-01 2025-03-31 15430379 2025-03-31 15430379 2024-03-31 15430379 core:Subsidiary1 2024-04-01 2025-03-31 15430379 bus:Director5 2024-04-01 2025-03-31 15430379 core:WithinOneYear 2025-03-31 15430379 core:ShareCapital 2025-03-31 15430379 core:SharePremium 2025-03-31 15430379 core:RetainedEarningsAccumulatedLosses 2025-03-31 15430379 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-03-31 15430379 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 15430379 core:Non-currentFinancialInstruments 2025-03-31 15430379 bus:Director1 2024-04-01 2025-03-31 15430379 bus:SmallEntities 2024-04-01 2025-03-31 15430379 bus:Audited 2024-04-01 2025-03-31 15430379 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 15430379 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 15430379 bus:FullAccounts 2024-04-01 2025-03-31
COMPANY REGISTRATION NUMBER: 15430379

Interneuron Group Limited

Filleted Financial Statements

31 March 2025

Interneuron Group Limited

Statement of Financial Position

31 March 2025

| 2025
Note | £ | £

Fixed assets

Investments | 5 |  | 753,114

Current assets

Debtors | 6 | 1,019 |
Cash at bank and in hand | 28,298 |
| -------- |
| 29,317 |

Creditors: amounts falling due within one year | 7 | 910,974 |
| --------- |
Net current liabilities |  | 881,657
|  | ---------
Total assets less current liabilities |  | ( 128,543)
|  | ---------
Net liabilities |  | ( 128,543)
|  | ---------

Capital and reserves

Called up share capital |  | 125
Share premium account |  | 143,975
Profit and loss account |  | ( 272,643)
|  | ---------
Shareholders deficit |  | ( 128,543)
|  | ---------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements were approved by the board of directors and authorised for issue on 19 December 2025 , and are signed on behalf of the board by:

Mr R Pugmire
Director

Company registration number: 15430379

Interneuron Group Limited

Notes to the Financial Statements

Year ended 31 March 2025
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Union Mills, 9 Dewsbury Road, Leeds, LS11 5DD, England.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
The financial statements have been prepared on a going concern basis assuming the ongoing support of the holding company to the business.
Investments
Fixed asset investments are initially recorded at cost, and subsequently stated at cost less any accumulated impairment losses.
Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.
Investments in associates
Investments in associates accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in associates accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the associate arising before or after the date of acquisition.
Investments in joint ventures
Investments in jointly controlled entities accounted for in accordance with the cost model are recorded at cost less any accumulated impairment losses. Investments in jointly controlled entities accounted for in accordance with the fair value model are initially recorded at the transaction price. At each reporting date, the investments are measured at fair value, with changes in fair value recognised in other comprehensive income/profit or loss. Where it is impracticable to measure fair value reliably the cost model will be adopted. Dividends and other distributions received from the investment are recognised as income without regard to whether the distributions are from accumulated profits of the joint venture arising before or after the date of acquisition.
Impairment of fixed assets
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. For the purposes of impairment testing, when it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that largely independent of the cash inflows from other assets or groups of assets. For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.
Finance leases and hire purchase contracts
Assets held under finance leases and hire purchase contracts are recognised in the statement of financial position as assets and liabilities at the lower of the fair value of the assets and the present value of the minimum lease payments, which is determined at the inception of the lease term. Any initial direct costs of the lease are added to the amount recognised as an asset. Lease payments are apportioned between the finance charges and reduction of the outstanding lease liability using the effective interest method. Finance charges are allocated to each period so as to produce a constant rate of interest on the remaining balance of the liability.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
4. Employee numbers
The average number of persons employed by the company during the year amounted to 2 .
5. Investments

| Shares in group undertakings
| £
Cost |
At 1 April 2024 | –
Additions | 753,114
| ---------
At 31 March 2025 | 753,114
| ---------
Impairment |
At 1 April 2024 and 31 March 2025 | –
| ---------

Carrying amount |
At 31 March 2025 | 753,114
| ---------

Subsidiaries, associates and other investments

| Class of share | Percentage of shares held
Subsidiary undertakings |  |
Interneuron Limited | Ordinary | 100

6. Debtors

| 2025
| £
Other debtors | 1,019
| -------

7. Creditors: amounts falling due within one year

| 2025
| £
Trade creditors | 31
Amounts owed to group undertakings and undertakings in which the company has a participating interest | 743,697
Social security and other taxes | 6,276
Other creditors | 160,970
| ---------
| 910,974
| ---------

8. Summary audit opinion
The auditor's report dated 19 December 2025 was unqualified .
The senior statutory auditor was Andrew Wild BA FCA , for and on behalf of TLP Consulting Limited .
9. Directors' advances, credits and guarantees
During the year the directors received advances of £nil and repaid £nil to the company.